HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Selective activation of alpha1A-adrenergic receptors in neonatal cardiac myocytes is sufficient to cause hypertrophy and differential regulation of alpha1-adrenergic receptor subtype mRNAs.

Abstract
Prolonged stimulation of cardiac alpha1-adrenergic receptors causes myocyte hypertrophy, although the receptor subtypes involved remain controversial. We have used a potent and selective alpha1A agonist, A-61603, to test whether activation of the alpha1A-adrenergic receptor subtype is sufficient to mediate the morphological, biochemical and molecular alterations associated with cardiomyocyte hypertrophy. In neonatal rat cardiomyocyte cultures, 48 h incubation with 50 nm A-61603 led to a marked increase in myocardial cell size that was associated with a significant elevation in the rate of protein synthesis. The increased rate of incorporation of radiolabelled amino acids into protein stimulated by A-61603 was totally abolished by the selective alpha1A antagonist KMD-3213. A-61603 increased ANF secretion three-fold, and ANF mRNA 12-fold above control levels in cardiomyocyte cultures. RNase protection analysis demonstrated a A-61603-mediated two to three-fold increase in alpha1A-adrenergic receptor mRNA with a concomitant 50% decrease in alpha1B mRNA levels by 48 h. Identical responses of differential regulation of alpha1A- and alpha1B-adrenergic receptor mRNA were observed with phenylephrine. Both the stimulation of alpha1A- and repression alpha1B-adrenergic receptor mRNA caused by A-61603 could be abolished by 10-20 nm KMD-3213. The present data provide evidence that selective activation of alpha 1A-adrenergic receptors on cardiomyocytes is sufficient to mediate the phenotypic changes associated with cardiac hypertrophy. In addition, the differential regulation of alpha1A and alpha1B mRNA in response to selective alpha1A-adrenergic receptor stimulation suggests that cross-talk between receptor subtypes may be involved in regulating receptor populations during chronic agonist exposure.
AuthorsD J Autelitano, E A Woodcock
JournalJournal of molecular and cellular cardiology (J Mol Cell Cardiol) Vol. 30 Issue 8 Pg. 1515-23 (Aug 1998) ISSN: 0022-2828 [Print] England
PMID9737938 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright 1998 Academic Press.
Chemical References
  • A 61603
  • Adra1a protein, rat
  • Adra1b protein, rat
  • Adrenergic alpha-Agonists
  • Imidazoles
  • Indoles
  • Proteins
  • RNA, Messenger
  • Receptors, Adrenergic, alpha-1
  • Tetrahydronaphthalenes
  • Atrial Natriuretic Factor
  • Propranolol
  • silodosin
Topics
  • Adrenergic alpha-Agonists (pharmacology)
  • Animals
  • Animals, Newborn
  • Atrial Natriuretic Factor (metabolism)
  • Cardiomegaly (pathology)
  • Cells, Cultured
  • Heart (growth & development)
  • Imidazoles (pharmacology)
  • Indoles (pharmacology)
  • Myocardium (cytology)
  • Propranolol (pharmacology)
  • Proteins (metabolism)
  • RNA, Messenger
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Adrenergic, alpha-1 (drug effects, genetics, metabolism)
  • Tetrahydronaphthalenes (pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: